losartan has been researched along with HbS Disease in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Guimarães-Nobre, CC | 1 |
| Mendonça-Reis, E | 1 |
| Teixeira-Alves, LR | 1 |
| Miranda-Alves, L | 1 |
| Berto-Junior, C | 1 |
| Quinn, CT | 1 |
| Saraf, SL | 1 |
| Gordeuk, VR | 1 |
| Fitzhugh, CD | 1 |
| Creary, SE | 1 |
| Bodas, P | 1 |
| George, A | 1 |
| Raj, AB | 1 |
| Nero, AC | 1 |
| Terrell, CE | 1 |
| McCord, L | 1 |
| Lane, A | 1 |
| Ackerman, HC | 1 |
| Yang, Y | 1 |
| Niss, O | 1 |
| Taylor, MD | 1 |
| Devarajan, P | 1 |
| Malik, P | 2 |
| Roy, S | 1 |
| Rai, P | 1 |
| Eiymo Mwa Mpollo, MS | 1 |
| Chang, KH | 1 |
| Rizvi, T | 1 |
| Shanmukhappa, SK | 1 |
| VandenHeuvel, K | 1 |
| Aronow, B | 1 |
| Inagami, T | 1 |
| Cancelas, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Losartan to Reverse Sickle Nephropathy[NCT01479439] | Phase 2 | 36 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of participants who have a ≥25% reduction in urinary albumin-to-creatinine ratio (UACR) from baseline to 6 months. This is a categorical outcome (yes/no).~We hypothesized and pre-specified that ≥30% of the subjects in the microalbuminuria group would meet this outcome." (NCT01479439)
Timeframe: Baseline and 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan - No Albuminuria | 1 |
| Losartan - Microalbuminuria | 7 |
| Losartan - Macroalbuminuria | 5 |
Fold-change in creatinine clearance by 24h urine collection (GFR-CrCl) from baseline (NCT01479439)
Timeframe: Baseline and 6 months
| Intervention | Fold-change (Median) |
|---|---|
| No Albuminuria (NoA) | 0.06 |
| Microalbuminuria (MicroA) | 0.12 |
| Macroalbuminuria | 0.05 |
Fold-change in UACR from baseline (NCT01479439)
Timeframe: Baseline and 6 months
| Intervention | Fold-change (Median) |
|---|---|
| No Albuminuria (NoA) | 0.08 |
| Microalbuminuria (MicroA) | -0.46 |
| Macroalbuminuria | -0.74 |
1 trial available for losartan and HbS Disease
| Article | Year |
|---|---|
Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
Topics: Adolescent; Adult; Age Factors; Albuminuria; Anemia, Sickle Cell; Child; Female; Glomerular Filtrati | 2017 |
2 other studies available for losartan and HbS Disease
| Article | Year |
|---|---|
ATR1 Angiotensin II Receptor Reduces Hemoglobin S Polymerization, Phosphatidylserine Exposure, and Increases Deformability of Sickle Cell Disease Erythrocytes.
Topics: Acrylates; Anemia, Sickle Cell; Angiotensin II; Annexin A5; Erythrocytes; Hemoglobin, Sickle; Humans | 2022 |
Angiotensin receptor signaling in sickle cell anemia has a reno-protective effect on urine concentrating ability but results in sickle glomerulopathy.
Topics: Adult; Anemia, Sickle Cell; Angiotensin II Type 1 Receptor Blockers; Animals; Captopril; Child; Dise | 2018 |